Anti-tuberculosis activity of Rivaroxabane in silico and in vitro-Reference-Cited by-同舟云学术

Anti-tuberculosis activity of Rivaroxabane in silico and in vitro

Published:2023-07-06 Issue:3 Volume:67 Page:207-213
ISSN:2524-2431
Container-title:Doklady of the National Academy of Sciences of Belarus
language:
Short-container-title:Dokl. Akad. nauk

Author:

Lakhvich T. T.¹,Ryneiskaya V. M.¹,Golyak N. S.¹,Yurkshtovich N. K.²,Nasennikava K. E.²,Lakhvich F. A.³

Affiliation:

1. Belarusian State Medical University

2. State company “Academpharm”

3. Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus

Abstract

The activity of Rivaroxoban of oxazolidinone series against Mycobacterium terrae was investigated in silico and in vitro. In silico studies have shown a high binding affinity of Rivaroxaban to β-ketoacyl[ACP]synthase I that plays a key role in the biosynthesis of mycolic acids, being the components of the mycobacterial cell wall. In the molecular docking study, two main binding sites of Rivaroxaban with protein were predicted and evaluated: the minimum binding energies were found for the both sites with the values of –10.26 kcal/mol and –8.99 kcal/mol. A solution of Rivaroxaban (200 μg/ml) has been shown to inhibit the growth of a Mycobacterium terrae culture. The data obtained open up the prospect of developing new effective anti-tuberculosis drugs of oxazolidinone series.

Publisher

Publishing House Belorusskaya Nauka

Subject

General Medicine

Reference10 articles.

1. Leimane V., Riekstina V., Holtz T., Zarovska E., Skripconoka V., Thorpe L. E., Laserson K. F., Wells C. D. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet, 2005, vol. 365, no. 9456, pp 318–326. https://doi.org/10.1016/s0140-6736(05)17786-1

2. Global tuberculosis report 1997–2021. World Health Organization. Available at: https://www.who.int/tb/publications/global_report/en/ (accessed 01 June 2022).

3. Li K., Schurig-Briccio L. A., Feng X., Upadhyay A., Pujari V., Lechartier B., Fontes F. L. [et al.]. Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases. Journal of Medicinal Chemistry, 2014, vol. 57, no. 7, pp. 3126−3139. https://doi.org/10.1021/jm500131shttps://doi.org/10.3947/ic.2019.51.2.142

4. Lakhvich T. T., Zushchik P. Yu., Lakhvich A. T. Rational design of the model of acyclic analogues of hydroxyisonipecotic acids. BGMU v avangarde meditsinskoi nauki i praktiki [Advances in medicine and medical sciences: collection of Belarusian state medical university]. Minsk, 2019, vol. 9, pp. 389–399 (in Russian).

5. Lakhvich T. T., Borava M. I.., Ryneiskaya V. M. In silico SAR studies of oxazolidinones as potential anti-tuberculosis drugs. BGMU v avangarde meditsinskoi nauki i praktiki [Advances in medicine and medical sciences: collection of Belarusian state medical university]. Minsk, 2019, iss. 12, vol. 2, pp. 200–205 (in Russian).